个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Chen, X.[1] * ; Hu, C.[2] ; Wang, W.[3] ; Zou, Q.[4] ; Li, J.[5] ; Lin, Q.[6] ; Zhu, X.[7] ; Jiang, Y.[8] ; Sun, Y.[9] ; Shen, L.[10] ; Wang, L.[11] ; Zou, G.[12] ; Lin, X.[13] ; Wang, Y.[14] ; Lin, S.[15] ; Li, M.[16] ; Ao, R.[17,18] ; Xu, R.[19] ; Lin, H.[20] ; Wang, R.[21] ;
机构： [1]Univ Chinese Acad Sci, Canc Hosp, Radiat Oncol, Hangzhou, Peoples R China [2]Fudan Univ, Shanghai Canc Ctr, Radiat Oncol, Shanghai, Peoples R China [3]Hunan Canc Hosp, Med Oncol, Changsha, Peoples R China [4]Guangzhou Med Univ, Ctr Canc, Med Oncol, Guangzhou, Peoples R China [5]Jiangxi Canc Hosp, Radiat Oncol, Nanchang, Jiangxi, Peoples R China [6]Xiamen Univ, Affiliated Hosp 1, Radiat Oncol, Xiamen, Peoples R China [7]Guangxi Med Univ, Affiliated Tumor Hosp, Radiat Oncol, Nanning, Peoples R China [8]Shantou Univ, Affiliated Canc Hosp, Radiat Oncol, Shantou, Peoples R China [9]Beijing Canc Hosp, Radiat Oncol, Beijing, Peoples R China [10]Cent South Univ, Xiangya Hosp, Med Oncol, Changsha, Peoples R China [11]Hainan Gen Hosp, Med Oncol, Haikou, Hainan, Peoples R China [12]Panyu Cent Hosp, Med Oncol, Guangzhou, Peoples R China [13]Fujian Med Univ Union Hosp, Med Oncol, Fuzhou, Peoples R China [14]Chongqing Canc Hosp, Radiat Oncol, Chongqing, Peoples R China [15]Fujian Canc Hosp, Radiat Oncol, Fuzhou, Peoples R China [16]Zhongshan Peoples Hosp, Radiat Oncol, Zhongshan, Peoples R China [17]Sichuan Acad Med Sci, Ctr Canc, Chengdu, Peoples R China [18]Sichuan Prov Peoples Hosp, Chengdu, Peoples R China [19]Shenzhen Peoples Hosp, Med Oncol, Shenzhen, Peoples R China [20]Hainan Med Univ, Affiliated Hosp 2, Med Oncol, Haikou, Hainan, Peoples R China [21]Guangxi Med Univ, Affiliated Hosp 1, Radiat Oncol, Nanning, Peoples R China
出处：
DOI： 10.1016/j.annonc.2021.08.1319
ISSN：
基金：
Akeso Biopharma, Inc.
语种：
外文
被引次数：
WOS：
中科院分区：
出版当年[2021]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2021]版：
Q1 ONCOLOGY
最新[2024]版：
Q1 ONCOLOGY

影响因子： 最新[2024版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者机构： [1]Univ Chinese Acad Sci, Canc Hosp, Radiat Oncol, Hangzhou, Peoples R China
推荐引用方式(GB/T 7714)：
Chen X.,Hu C.,Wang W.,et al.A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results[J].ANNALS OF ONCOLOGY.2021,32:S806-S806.doi:10.1016/j.annonc.2021.08.1319.
APA：
Chen, X.,Hu, C.,Wang, W.,Zou, Q.,Li, J....&Wang, R..(2021).A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results.ANNALS OF ONCOLOGY,32,
MLA：
Chen, X.,et al."A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results".ANNALS OF ONCOLOGY 32.(2021):S806-S806

资源点击量：42313 今日访问量：0 总访问量：1365 更新日期：2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号